Population survey on melanoma
Through the population survey, the health and quality of life of people both with and without melanoma will be mapped. In this way, we obtain the necessary knowledge about how common different late effects are, and who is affected, for example based on what kind of treatment they have received.
It can be difficult to live with late effects after cancer treatment, and it is important for this patient group that we get an overview of the burden and duration of late effects and how these affect quality of life. We use validated questionnaires, mainly from the European Organisation for Research and Treatment of Cancer.
Therefore, the Cancer Registry of Norway invites everyone who gets melanoma from 1 January 2021 to a population survey on health and life sensitivity.
More than 2300 new cases each year
Every year, more than 2300 Norwegians are diagnosed with melanoma. Survival is close to 90 percent, and in 2019, 12,493 people were alive more than ten years after their melanoma diagnosis.
We know that some struggle with chronic fatigue and lymphedema (after lymph node removal), but we do not know enough about the burden of late effects in this group.
This also applies to the ever-growing group of people who receive immunotherapy and who we know may experience various inflammations after their treatment.
